No results for ‘’
Biocon Ltd
₹415.50
(0.40%)
Sat, 20 Jun 2026, 04:44 pm
Health Technology
Pharmaceuticals: Major
24.5KBiocon Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 24.82 | 22.74 | 19.10 | 11.93 | 19.16 | 18.47 | 13.78 | 10.66 | 20.34 | 18.88 | 17.21 | 36.60 | 94.77 | 40.20 | 42.94 | 66.07 | 61.73 | 53.33 | 30.91 | 40.35 |
| Price to book ratio | 5.02 | 4.54 | 2.90 | 1.91 | 3.24 | 3.38 | 2.10 | 2.04 | 2.80 | 2.87 | 2.39 | 4.69 | 6.88 | 6.01 | 4.84 | 6.43 | 4.76 | 1.39 | 1.60 | 1.89 |
| Price to sales ratio | 5.47 | 4.62 | 4.07 | 1.78 | 2.37 | 2.45 | 2.30 | 2.24 | 2.95 | 3.07 | 2.83 | 5.76 | 8.75 | 6.67 | 5.16 | 6.86 | 4.89 | 2.23 | 2.15 | 2.69 |
| Price to cash flow ratio | 52.03 | 31.11 | 13.24 | 27.77 | 12.89 | 8.44 | 8.35 | 10.78 | 14.64 | 38.66 | 23.68 | 31.08 | 53.58 | 32.11 | 24.94 | 44.12 | 35.53 | 16.56 | 14.04 | 11.54 |
| Enterprise value | 4426Cr | 4736Cr | 4533Cr | 3413Cr | 6034Cr | 6723Cr | 3922Cr | 4523Cr | 7857Cr | 9512Cr | 9776Cr | 22952Cr | 35988Cr | 37534Cr | 33665Cr | 51061Cr | 43243Cr | 43592Cr | 50803Cr | 60386Cr |
| Enterprise value to EBITDA ratio | 19.61 | 17.37 | 15.40 | 10.26 | 12.53 | 11.88 | 8.17 | 8.85 | 15.22 | 17.20 | 14.89 | 26.49 | 47.90 | 27.77 | 21.70 | 30.43 | 21.40 | 14.22 | 12.10 | 18.11 |
| Debt to equity ratio | 0.12 | 0.18 | 0.18 | 0.35 | 0.30 | 0.17 | 0.10 | 0.08 | 0.29 | 0.34 | 0.62 | 0.49 | 0.44 | 0.40 | 0.40 | 0.59 | 0.61 | 1.01 | 0.82 | 0.85 |
| Return on equity % | 21.36 | 20.47 | 17.59 | 16.05 | 17.94 | 19.39 | 15.72 | 20.49 | 14.47 | 15.80 | 15.07 | 13.77 | 7.43 | 16.05 | 12.14 | 10.33 | 8.08 | 3.52 | 5.43 | 4.89 |
Biocon Ltd Ratios
The Biocon Ltd Ratios page provides a complete fundamental analysis of Biocon Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Biocon Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Biocon Ltd (NSE: BIOCON, BSE: 532523) is currently trading at ₹415.50, with a market capitalization of ₹67315.61Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Biocon Ltd remains a key stock for fundamental analysis using Biocon Ltd Ratios.
Biocon Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Biocon Ltd P/E ratio currently stands at 40.35, making it one of the most tracked metrics in Biocon Ltd Ratios.
Historically, the Biocon Ltd P/E ratio has shown strong fluctuations:
- 2024: 40.35
- 2023: 30.91
- 2022: 53.33
- 2021: 61.73
- 2020: 66.07
The rising Biocon Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Biocon Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.89.
Historical P/B trend:
- 2024: 1.89
- 2023: 1.60
- 2022: 1.39
- 2021: 4.76
Biocon Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Biocon Ltd P/S ratio currently stands at 2.69, an important part of Biocon Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 2.69
- 2023: 2.15
- 2022: 2.23
- 2021: 4.89
The rising Biocon Ltd P/S ratio indicates improved revenue valuation by investors.
Biocon Ltd Price to Cash Flow Ratio (P/CF)
The Biocon Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 11.54.
Historical Biocon Ltd Price to Cash Flow Ratio:
- 2024: 11.54
- 2023: 14.04
- 2022: 16.56
- 2021: 35.53
- 2020: 44.12
The declining Biocon Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Biocon Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Biocon Ltd EV currently stands at ₹60386Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 60386Cr
- 2023: 50803Cr
- 2022: 43592Cr
- 2021: 43243Cr
Biocon Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Biocon Ltd EV/EBITDA ratio is currently 18.11, a key metric in Biocon Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 18.11
- 2023: 12.10
- 2022: 14.22
- 2021: 21.40
Higher Biocon Ltd EV/EBITDA suggests premium valuation.
Biocon Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Biocon Ltd D/E ratio is currently 0.85, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.85
- 2023: 0.82
- 2022: 1.01
- 2021: 0.61
Biocon Ltd maintains moderate leverage with manageable risk.
Return on Equity (ROE %)
The Biocon Ltd ROE currently stands at 4.89%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 4.89
- 2023: 5.43
- 2022: 3.52
- 2021: 8.08
Declining ROE indicates pressure on profitability.
Biocon Ltd Ratios Analysis Summary
The Biocon Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Biocon Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Biocon Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.